Kirk Steptoe, MD
Internal Medicine · Lexington, SCNPI 1942212949
Payments from drug & device makers
Across 284 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$636
- AstraZeneca$606
- Lilly USA, LLC$448
- Pfizer$397
- Amgen$234
- Neurocrine Biosciences, Inc.$215
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $636 |
| AstraZeneca | 33 | $606 |
| Lilly USA, LLC | 31 | $448 |
| Pfizer | 27 | $397 |
| Amgen | 15 | $234 |
| Neurocrine Biosciences, Inc. | 9 | $215 |
| Dexcom, Inc. | 8 | $203 |
| Novartis | 11 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $196 |
| AbbVie(2 entities) | 11 | $179 |
| Sanofi-aventis U.S. LLC | 7 | $138 |
| GSK | 8 | $121 |
| Exact Sciences | 7 | $116 |
| Daiichi Sankyo Inc. | 5 | $93 |
| Johnson & Johnson | 6 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Astellas Pharma US Inc | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Boehringer Ingelheim | 5 | $73 |
| Abbott | 4 | $69 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Cequr Corporation | 2 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 4 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $28 |
| Merck | 1 | $25 |
| Bristol Myers Squibb | 1 | $20 |
| Stryker | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$4,831 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $139,183 |
| JardianceEmpagliflozin | 93 | $82,286 |
| JanuviaSitagliptin Phosphate | 101 | $74,108 |
| OzempicSemaglutide | 54 | $69,596 |
| NuplazidPimavanserin Tartrate | 11 | $50,646 |
| TrulicityDulaglutide | 25 | $41,454 |
| FarxigaDapagliflozin Propanediol | 33 | $35,843 |
| Glatiramer Acetate | 12 | $30,265 |
| XareltoRivaroxaban | 41 | $24,394 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $20,449 |
| EntrestoSacubitril/Valsartan | 24 | $16,432 |
| MyrbetriqMirabegron | 36 | $13,525 |
| RybelsusSemaglutide | 11 | $9,733 |
| Novolog FlexpenInsulin Aspart | 29 | $8,804 |
| Atorvastatin Calcium | 506 | $7,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $397 | $139,183232 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $73 | $87,963105 claims |
| MerckJanuvia, Belsomra | $25 | $80,809116 claims |
| Novo NordiskOzempic, Rybelsus | $636 | $79,32965 claims |
| Acadia Pharmaceuticals IncNuplazid | $12 | $50,64611 claims |
| AstraZenecaFarxiga, Nexium | $606 | $42,66546 claims |
| Lilly USA, LLCTrulicity | $448 | $41,45425 claims |
| GSKAnoro Ellipta, Incruse Ellipta | $121 | $24,76947 claims |
| Johnson & JohnsonXarelto | $85 | $24,39441 claims |
| NovartisEntresto | $197 | $16,43224 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $13,52536 claims |
| Aimmune Therapeutics, Inc.Zenpep | $35 | $6,09413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Lexington
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.